0MJF Stock Chart & Stats
kr67.17
kr2.42(3.59%)
At close: 4:00 PM EDT
kr67.17
kr2.42(3.59%)
Day’s Range― - ―
52-Week Rangekr56.40 - kr111.80
Previous CloseN/A
Volume40.66K
Average Volume (3M)48.26K
Market Cap
kr17.27B
Enterprise Valuekr16.13K
Total Cash (Recent Filing)kr640.00M
Total Debt (Recent Filing)kr554.00M
Price to Earnings (P/E)35.4
Beta1.04
Next Earnings
Nov 05, 2026EPS Estimate
0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.38
Shares Outstanding234,974,400
10 Day Avg. Volume34,042
30 Day Avg. Volume48,264
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr72.00Price Target Upside7.19% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ambu News
0MJF FAQ
What was Ambu A/S Class B’s price range in the past 12 months?
Ambu A/S Class B lowest share price was kr56.40 and its highest was kr111.80 in the past 12 months.
What is Ambu A/S Class B’s market cap?
Ambu A/S Class B’s market cap is kr17.27B.
When is Ambu A/S Class B’s upcoming earnings report date?
Ambu A/S Class B’s upcoming earnings report date is Nov 05, 2026 which is in 41 days.
How were Ambu A/S Class B’s earnings last quarter?
Ambu A/S Class B released its earnings results on Aug 25, 2026. The company reported kr0.595 earnings per share for the quarter, missing the consensus estimate of kr0.621 by -kr0.026.
Is Ambu A/S Class B overvalued?
According to Wall Street analysts Ambu A/S Class B’s price is currently Undervalued.
Does Ambu A/S Class B pay dividends?
Ambu A/S Class B does not currently pay dividends.
What is Ambu A/S Class B’s EPS estimate?
Ambu A/S Class B’s EPS estimate is 0.87.
How many shares outstanding does Ambu A/S Class B have?
Ambu A/S Class B has 234,974,400 shares outstanding.
What happened to Ambu A/S Class B’s price movement after its last earnings report?
Ambu A/S Class B reported an EPS of kr0.595 in its last earnings report, missing expectations of kr0.621. Following the earnings report the stock price went up 0.784%.
Which hedge fund is a major shareholder of Ambu A/S Class B?
Currently, no hedge funds are holding shares in GB:0MJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ambu A/S Class B
Established in 1937 and headquartered in Ballerup, Denmark, Ambu A/S is a global medical technology company specializing in the design, manufacture, and sale of advanced medical devices. The company serves hospitals, clinics, and emergency services worldwide, providing essential healthcare solutions across key disciplines such as visualization, anesthesia, and patient monitoring and diagnostics. Their extensive product portfolio includes sophisticated endoscopy equipment like bronchoscopes and dedicated monitors. For neurology, Ambu offers EEG and EMG electrodes, as well as tools for EMG-guided injections and intraoperative monitoring systems. Cardiology solutions feature ECG electrodes. A substantial portion of their offerings is dedicated to airway management and anesthesia, comprising specialized bronchoscopes, video laryngoscopes, various intubation tubes (double and single lumen), endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitation devices. Additionally, Ambu provides critical emergency and training products, including extrication collars, CPR breathing barriers, and training manikins.
0MJF Company Deck
0MJF Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong top-line momentum driven by Endoscopy (Respiratory and Urology/ENT/GI) with meaningful product and platform progress, robust cash generation and improved gross margin. Offsetting these positives were modest ongoing weakness in Anesthesia & Patient Monitoring, FX headwinds, residual tariff uncertainty and one-off commercial and project costs that depressed adjusted EBIT in Q3. Management confirmed updated guidance (~10% organic growth) and expects Q4 margin improvement driven by higher growth, tariff reclaims and operating leverage, while retaining medium-term margin ambitions.View all GB:0MJF earnings summaries0MJF Stock 12 Month Forecast
Average Price Target
kr72.00
▲(7.19% Upside)